Literature DB >> 991914

Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen.

N Galili, D Naor, B Asjö, G Klein.   

Abstract

Trinitrophenylated Moloney virus-induced YAC cells induced a higher cytotoxic antibody response and better protection against small tumor cell doses in syngeneic, low-responsive strain A mice than nonmodified YAC cells that had been inactivated by irradiation or mitomycin C treatment. The results indicated that genetically determined low responsiveness to a virally induced antigen can be overcome, at least to some extent, by coupling the immunizing cells to a strong immunogenic hapten.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 991914     DOI： 10.1002/eji.1830060705

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  20 in total

1.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  The role of contrasuppression in tumor regression.

Authors:  P M Flood; A Friedman; J Freedman; B Horvat; P Reuter; W Ptak
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.

Authors:  C Uyttenhove; J Van Snick; T Boon
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

5.  Immunotherapy of tumor-bearing mice utilizing virus help.

Authors:  Y Shimizu; K Hasumi; K Masubuchi; Y Okudaira
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.

Authors:  A Vyakarnam; P J Lachmann; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

7.  Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

Authors:  A Van Pel; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens.

Authors:  Y S Kim; R Slomski; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma.

Authors:  P Nanni; C de Giovanni; P L Lollini; G Nicoletti; G Prodi
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

10.  The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.

Authors:  T Yoshioka; M Fukuzawa; Y Takai; N Wakamiya; S Ueda; S Kato; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.